Fibrostenotic Eosinophilic Esophagitis: Assessment Tools

University of Colorado, Denver250 enrolled

Overview

This protocol addresses a central hypothesis that fibrostenotic Eosinophilic Esophagitis (EoE) is characterized by abnormal esophageal structure and compliance compared to non fibrostenotic EoE and that distinctive cellular and molecular profiles predict the fibrostenotic phenotype. This study aims to define and assess the changes that occur in the structure and dynamics of the esophageal wall in pediatric Eosinophilic Esophagitis along with characterizing the histologic and molecular patterns in fibrostenotic EoE.

Study Type

OBSERVATIONAL

Enrollment

250

Conditions

Eosinophilic Esophagitis

Eligibility

Sex: ALLMin age: 5 YearsMax age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Scheduled to undergo a clinical upper endoscopy with biopsy Exclusion Criteria: * Known connective tissue disorder * Increased risk of bleeding * Inflammatory bowel disease, celiac disease, eosinophilic gastroenteritis, or any autoimmune disease * Other esophageal disease including known achalasia; history of caustic ingestion, esophageal surgery esophageal stricture for other known reason or other esophageal injury. * Use of oral or intravenous steroids in the preceding 60 days. (Swallowed topical fluticasone, budesonide, etc not included as exclusion criteria.)

Locations (1)

Children's Hospital Colorado

Aurora, Colorado, United States

RECRUITING

Outcomes

Primary Outcomes

Stricture, as measured by endoscopic assessment

Time frame: Day 1

Secondary Outcomes

Decreased esophageal distensibility, as determined by EndoFlip

Time frame: Day 1

Central Contacts

Cassandra Burger

CONTACT

720-777-5739 cassandra.burger@childrenscolorado.org

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.